Claims
- 1. A method for treating a Pin1-associated state in a subject comprising administering to a subject an effective amount of a fredericamycin A compound such that the Pin1-associated state is treated.
- 2. The method of claim 1, wherein the Pin1-associated state is a cyclin D1 elevated state.
- 3. The method of claim 1, wherein the Pin1-associated state is neoplastic transformation.
- 4. The method of claim 1, wherein the Pin1-associated state is cancer.
- 5. The method of claim 1, wherein the Pin1-associated state is tumor growth.
- 6. The method of claim 1, wherein the treating comprises inhibiting tumor growth.
- 7. The method of claim 1, wherein the treating comprises preventing the occurrence of tumor growth in the subject.
- 8. The method of claim 1, wherein the treating comprises reducing the growth of a pre-existing tumor in the subject.
- 9. The method of claim 1, wherein the Pin1-associated state is colon cancer.
- 10. The method of claim 1, wherein the Pin1-associated state is breast cancer.
- 11. The method of claim 1, wherein the Pin1-associated state is a sarcoma.
- 12. The method of claim 1, wherein the Pin1-associated state is a malignant lymphoma.
- 13. The method of claim 1, wherein the Pin1-associated state is esophageal cancer.
- 14. The method of claim 1, wherein the Pin1-associated state is caused by overexpression of Pin1.
- 15. The method of claim 1, wherein the Pin1-associated state is caused by DNA damage.
- 16. The method of claim 1, wherein the Pin1-associated state is caused by an oncogenic protein.
- 17. The method of claim 1, wherein the Pin1-associated state is caused by Ha-Ras.
- 18. The method of claim 1, wherein the fredericamycin A compound has Formula IX
- 19. The method of claim 1, wherein the fredericamycin A compound is fredericamycin A, or pharmaceutically acceptable salts, ester, or prodrugs thereof.
- 20. The method of claim 1, wherein the fredericamycin A compound has Formula III
- 21. The method of claim 1, wherein the fredericamycin A compound has Formula IV
- 22. The method of claim 1, wherein the fredericamycin A compound has Formula VI
- 23. The method of claim 1, wherein the fredericamycin A compound has Formula XI
- 24. The method of claim 1, wherein the fredericamycin A compound has Formula VII
- 25. The method of claims 1, wherein the fredericamycin A compound has Formula VIII:
- 26. The method of claim 1, wherein the fredericamycin A compound is a compound of the formulae:
- 27. The method of claim 1, wherein the fredericamycin A compound is a griseorhodin, or pharmacuetically acceptable salts, prodrugs, and esters thereof.
- 28. A method for treating cyclin D1 overexpression in a subject comprising administering to a subject an effective amount of a fredericamycin A compound such that cyclin D1 overexpression is treated.
- 29. The method of claim 28, wherein the cyclin D1 overexpression results in neoplastic transformation.
- 30. The method of claim 28, wherein the cyclin D1 overexpression results in tumor growth.
- 31. The method of claim 28, wherein the treating comprises inhibiting tumor growth.
- 32. The method of claim 28, wherein the treating comprises preventing the occurrence of tumor growth in the subject.
- 33. The method of claim 28, wherein the treating comprises reducing the growth of a pre-existing tumor in the subject.
- 34. The method of claim 28, wherein the cyclin D1 overexpression results in colon cancer.
- 35. The method of claim 28, wherein the cyclin D1 overexpression results in breast cancer.
- 36. The method of claim 28, wherein the cyclin D1 overexpression results in a sarcoma.
- 37. The method of claim 28, wherein the cyclin D1 overexpression results in a malignant lymphoma.
- 38. The method of claim 28, wherein cyclin D1 overexpression results in esophageal cancer.
- 39. The method of claim 28, wherein the cyclin D1 overexpression is caused by overexpression of Pin1.
- 40. The method of claim 28, wherein the cyclin D1 overexpression is caused by DNA damage.
- 41. The method of claim 28, wherein the cyclin D1 overexpression is caused by an oncogenic protein.
- 42. The method of claim 28, wherein cyclin Dl overexpression is caused by Ha-Ras.
- 43. The method of claim 28, wherein the fredericamycin A compound has Formula IX
- 44. The method of claim 28, wherein the fredericamycin A compound is fredericamycin A, or pharmacuetically acceptable salts, prodrugs, and esters thereof.
- 45. The method of claim 28, wherein the fredericamycin A compound has Formula III
- 46. The method of claim 28, wherein the fredericamycin A compound has Formula IV
- 47. The method of claim 28, wherein the fredericamycin A compound has Formula VI
- 48. The method of claim 28, wherein the fredericamycin A compound has Formula XI
- 49. The method of claim 28, wherein the fredericamycin A compound has Formula VII
- 50. The method of claim 28, wherein the fredericamycin A compound has Formula VIII
- 51. The method of claim 28, wherein the fredericamycin A compound is a compound of the formulae:
- 52. The method of claim 28, wherein the fredericamycin A compound is a griseorhodin, or a pharmaceutically acceptable salt, prodrug or ester thereof.
- 53. A method for treating tumor growth in a subject comprising administering to a subject an effective amount of a fredericamycin A compound having Formula VI
- 54. The method of claim 53, wherein the treating comprises inhibiting tumor growth.
- 55. The method of claim 53, wherein the treating comprises preventing the occurrence of tumor growth in the subject.
- 56. The method of claim 53, wherein the treating comprises reducing the growth of a pre-existing tumor in the subject.
- 57. The method of claim 53, wherein the tumor growth is colon cancer.
- 58. The method of claim 53, wherein the tumor growth is breast cancer.
- 59. The method of claim 53, wherein the tumor growth is a sarcoma.
- 60. The method of claim 53, wherein the tumor growth is a malignant lymphoma.
- 61. The method of claim 53, wherein the tumor growth is esophageal cancer.
- 62. The method of claim 53, wherein the tumor growth is caused by overexpression of Pin1.
- 63. The method of claim 53, wherein the tumor growth is caused by DNA damage.
- 64. The method of claim 53, wherein the tumor growth is caused by an oncogenic protein.
- 65. The method of claim 53, wherein the tumor growth is caused by Ha-Ras.
- 66. The method of claim 53, wherein the tumor growth is caused by loss of Brca1 or a mutation of Brca1.
- 67. The method of claim 53, wherein the fredericamycin A compound has Formula VII:
- 68. The method of claim 53, wherein the fredericamycin A compound is a griseorhodin, or a pharmaceutically acceptable salt, prodrug, or ester thereof.
- 69. A packaged Pin1-associated state treatment, comprising a fredericamycin A compound packaged with instructions for using an effective amount of the fredericamycin A compound to treat a Pin1-associated state.
- 70. A packaged cyclin D1 overexpression treatment, comprising a fredericamycin A compound packaged with instructions for using an effective amount of the fredericamycin A compound to treat cyclin D1 overexpression.
- 71. A packaged cancer treatment, comprising a fredericamycin A compound packaged with instructions for using an effective amount of the fredericamycin A compound to treat cancer.
- 72. A method for treating a Pin1-associated state in a subject comprising administering to a subject an effective amount of a combination of a fredericamycin A compound and a hyperplastic inhibitory agent such that the Pin1-associated state is treated.
- 73. The method of claim 72, wherein the fredericamycin A compound has Formula IX
- 74. The method of claim 72, wherein the fredericamycin A compound is fredericamycin A, or pharmacuetically acceptable salts, prodrugs, and esters thereof.
- 75. The method of claim 72, wherein the fredericamycin A compound has Formula III:
- 76. The method of claim 72, wherein the fredericamycin A compound has Formula IV:
- 77. The method of claim 72, wherein the fredericamycin A compound has Formula VI:
- 78. The method of claim 72, wherein the fredericamycin A compound has Formula XI
- 79. The method of claim 72, wherein the fredericamycin A compound has Formula VII
- 80. The method of claim 72, wherein the fredericamycin A compound has Formula VIII:
- 81. The method of claim 72, wherein the fredericamycin A compound is a compound of the formulae:
- 82. The method of claim 72, wherein the fredericamycin A compound is a griseorhodin.
- 83. The method of claim 72, wherein the hyperplastic inhibitory agent is tamoxifen.
- 84. The method of claim 72, wherein the hyperplastic inhibitory agent is paclitaxel.
- 85. The method of claim 72, wherein the hyperplastic inhibitory agent is docetaxel.
- 86. The method of claim 72, wherein the hyperplastic inhibitory agent is interleukin-2.
- 87. The method of claim 72, wherein the hyperplastic inhibitory agent is rituximab.
- 88. The method of claim 72, wherein the hyperplastic inhibitory agent is tretinoin.
- 89. The method of claim 72, wherein the hyperplastic inhibitory agent methotrexate.
- 90. A method for treating cancer in a subject comprising administering to a subject an effective amount of a combination of a fredericamycin A compound and a hyperplastic inhibitory agent such that the cancer is treated.
- 91. A method for treating cyclin D1 overexpression in a subject comprising administering to a subject an effective amount of a combination of a fredericamycin A compound and a hyperplastic inhibitory agent such that the cyclin D1 overexpression is treated.
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional Patent Application No. ______, filed on Dec. 20, 2001, entitled “Methods of Inhibiting Pin1-Associated States Using a Fredericamycin A Compound;” and U.S. Provisional Patent Application No. 60/257,412, filed on Dec. 22, 2000. This application is related to U.S. patent application Ser. No. 09/726,464, filed Nov. 29, 2000; U.S. application Ser. No. 08/988,842, filed Dec. 11, 1997; and WO 99/12962, published Mar. 8, 1999. The entire contents of each of the aforementioned applications are hereby incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60342572 |
Dec 2001 |
US |
|
60257412 |
Dec 2000 |
US |